Breaking News

Aragen Launches CHOMax Platform to Accelerate Path from DNA to Clinical Supply

CHOMax’s approximate 10-month timeline is based on suitable, standard IgG monoclonal antibodies.

Author Image

By: Patrick Lavery

Content Marketing Editor

Cell Line development Lab at Aragen, Morgan Hill, USA

Aragen has announced CHOMax, a new cell line development and early manufacturing platform. The platform supports an integrated pathway from DNA to investigational new drug (IND)-enabling clinical supply. For suitable, standard immunoglobulin G (IgG) monoclonal antibodies, Aragen says that timeline can be reduced to approximately 10 months. Refined across more than 200 Chinese hamster ovary (CHO) programs, CHOMax integrates numerous factors. These include cell line and process development, ana...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters